Ottimo Pharma
Katherine Bell-McGuinn is a seasoned professional in clinical development and oncology, currently serving as the Senior Vice President of Clinical Development at Ottimo Pharma since February 2025. Prior to this role, Katherine was the Chief Medical Officer at 858 Therapeutics from November 2023 to February 2025 and held various leadership positions at AbbVie, including Vice President and Head of Oncology Early Development, from March 2020 to October 2023. Katherine's career also includes significant contributions at Eli Lilly and Company as a Medical Fellow and Senior Medical Advisor, and experience as an Assistant Attending Physician at Memorial Sloan Kettering Cancer Center. Katherine's educational background includes an M.D./Ph.D. in Pharmacology from The Johns Hopkins University School of Medicine, a residency in Internal Medicine at The Johns Hopkins Hospital, and degrees in Chemistry and Mathematics from Texas Lutheran University.
This person is not in any teams
This person is not in any offices
Ottimo Pharma
Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden. The Company boasts a world-class leadership team, including David Epstein as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, and James Sabry as Vice-Chair of the Board. Ottimo Pharma anticipates filing an IND in late 2025.